Compare CRDF & DAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRDF | DAVA |
|---|---|---|
| Founded | 1999 | 2000 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.1M | 80.3M |
| IPO Year | 2012 | 2015 |
| Metric | CRDF | DAVA |
|---|---|---|
| Price | $0.87 | $1.18 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 5 |
| Target Price | ★ $5.14 | $3.63 |
| AVG Volume (30 Days) | ★ 1.0M | 286.0K |
| Earning Date | 11-12-2026 | 12-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.37 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $365,993.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.70 |
| P/E Ratio | ★ N/A | $20.02 |
| Revenue Growth | ★ 49.61 | N/A |
| 52 Week Low | $0.71 | $1.16 |
| 52 Week High | $3.31 | $7.18 |
| Indicator | CRDF | DAVA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.
Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the UK, and it continues to generate the majority of revenue in the UK and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.